Abstract Submission FAQs and Guidelines 2021


Important Dates

Abstract Submission Opens
April 1, 2021

Abstract Submission Deadline
May 15, 2021 (5:00 PM EST)

Acceptance Notifications

Rolling Acceptance for Abstracts
June 2, 2021 for Oral Presentations

Late Breaker Submission:
Opens May 24, 2021

Late Breaker Submission Deadline
May 28, 2021 (5:00 PM EST)

Notification: June 2, 2021

Final Poster and Abstract for Virtual Posting Must be provided to RAD no later than June 4, 2021 at 12 noon (EST)

Important Information Regarding Oral Presentations

A list of abstracts that have been accepted as oral presentations will be posted to the Conference Agenda on or about June 2, 2021. Authors will be sent correspondence. If your abstract is listed as an oral presentation, and you do not receive correspondence, please email Patrice Melluso This email address is being protected from spambots. You need JavaScript enabled to view it. as soon as possible.

Please be aware of the following dates and requirements in the event you have been selected:

  • You will be notified by June 2, 2021
  • You will need to participate in a premeeting conference call for equipment testing and training on June 7, 2021
  • You will need to provide your presentation by June 8, 2021. Format will be MP4 or live. More details to follow upon acceptance

Frequently Asked Questions (FAQs)

  • Is there an abstract submission fee?
    Yes - US $50.00

    Are there rules about previous presentation of data?
    Encore presentations are permitted. All abstracts will undergo review by the Abstract Review Committee who will assess for scientific merit and novelty.

    Is a trial-in-progress abstract allowed?
    Yes

    Is there an author limit for abstracts?
    No

    Is there a word limit or character count to which we should adhere?
    700 words

    May we include figures and tables in the abstract?
    Yes

    May a non-author present on behalf of the authors?
    Yes, only if:
    • Presenter is not a company employee within the pharma industry
    • Presenter is a colleague attending the conference and presenting on behalf of authors who cannot attend

    Is Industry Sponsorship allowed?
    Yes

    Is Society Sponsorship required for admission?
    No

    Are QR codes allowed on the posters?
    No

    Do you have any policy regarding the usage of brand names or trademarks in abstracts or posters?
    Brand names or trademarks are not allowed - only generic names may be used.

    Will you accept an abstract presenting only the study design?
    It would be preferable if the abstract included the results/read outs; however, if they are not available at the time of submission but will be presented at the conference, that would be acceptable.

    What are the Embargo Rules, if any?
    • None for encores.
    • For primary disclosures, scientific dissemination should be reserved until after the Conference. Press releases and media coverage are allowed in advance of the Conference.

    Where will the abstracts be published?
    All accepted abstracts will be published in the British Journal of Dermatology Q4/2021 as well as on the RAD Website

    What is the Abstract Notification Date?
    Within approximately 1 week of abstract submission

    What is the pre-Conference abstract availability date/access venue?
    Saturday, June 12, 2021 - 5:00 PM EST

    What is the post-Conference abstract availability date/access venue?
    In perpetuity

    Is there a language requirement for the abstracts?
    English

Abstract Guidelines

As you prepare your submission to the Conference, please make note of the following details:
• All types of atopic dermatitis related research are eligible for submission.
• Abstract should address scientific questions, detail clinical observations, or contain primary scientific data.
• Encore presentations of data from previously presented research may be submitted.
• Abstracts may be submitted in English only.

Guidelines for Poster Presenters

A pdf file will be required for online posting.

Presenting Author Responsibilities

The presenting author must:

• Agree to the Confidentiality Policy on behalf of all parties involved with the abstract and communicate this policy to all involved parties. The Confidentiality Policy applies to both standard and late-breaking data submission from the time of abstract submission.

• Verify that, if necessary for the work reported, the clinical research represented in the abstract was approved by an appropriate ethics committee or institutional review board and that, if appropriate to the research, informed consent was obtained for all subjects.

• Verify that all coauthors are aware of the contents of the abstract and support its data.

• Agree, on behalf of all coauthors, to publication of the abstract in the final scientific program.

• For an abstract to be included in the final scientific program, it is mandatory for the presenting author to register for the symposium and to settle payment within 1 week of receiving the notification of abstract acceptance.

• Agree to present the abstract if it is selected for poster presentation at the RAD Conference. This includes being present during the scheduled time of a poster session. Accepted posters will be accessible to delegates in the poster exhibition area.

• Agree to list all potential conflicts of interest in the poster presentation if the abstract is accepted for presentation at the RAD Conference.

• Ensure that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journal Editors.

• Enter the name of the clinical trial registry and the trial registration number if the abstract reports on a registered clinical trial.
© 2021 The Foundation for Dermatology Education.
The Foundation for Dermatology Education is a registered 501(c)(3) nonprofit organization located in Chicago, IL.